Understand the source comparison
Best Research Peptides for Depression Research: Compound Comparison
Semax BDNF upregulation, hippocampal neurogenesis via ACTH(4-10) signaling 50–300 µg/kg intranasal, daily for 7–14 days Forced swim test, learned helplessness, Morris water maze 7–10 days (chronic administration) Best choice for stress-induced hippocampal atro
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semax
- BDNF upregulation, hippocampal neurogenesis via ACTH(4-10) signaling
- 50–300 µg/kg intranasal, daily for 7–14 days
- Forced swim test, learned helplessness, Morris water maze
- 7–10 days (chronic administration)
- Best choice for stress-induced hippocampal atrophy models; strong BDNF-TrkB pathway specificity makes it ideal for neuroplasticity hypotheses
- Selank
- GABAergic modulation, HPA axis suppression via tuftsin analog
- 100–300 µg/kg intranasal, daily for 14–21 days
- Elevated plus maze, light-dark box, restraint stress + corticosterone measurement
- 10–14 days (requires chronic dosing for GABAergic adaptation)
- Top candidate for anxiety-depression comorbidity and neuroendocrine dysregulation studies; cleaner mechanistic isolation than SSRIs
- P21 (CNTF fragment)
- CREB phosphorylation, synaptic plasticity, dendritic spine density
- 1–5 mg/kg subcutaneous, daily for 10–14 days
- Novel object recognition, reversal learning, tail suspension test
- 10–14 days (structural changes lag behavioural effects)
- Most relevant for cognitive-affective symptoms; prefrontal CREB signaling makes it distinct from monoamine-focused compounds
- BPC-157
- Gut-brain axis modulation, serotonergic and dopaminergic receptor upregulation
- 10–500 µg/kg subcutaneous or oral, daily for 14–28 days
- Chronic mild stress paradigm, sucrose preference test
- 14–21 days (requires extended administration)
- Useful for studying peripheral-central signaling (vagal nerve involvement); less studied than Semax/Selank but emerging in gut microbiome-depression research
- Cerebrolysin
- Multi-target neurotrophic effects (BDNF, GDNF, NGF upregulation)
- 2.5–5 mL/kg intraperitoneal, 3x weekly for 4 weeks
- Forced swim test, open field test, Morris water maze
- 14–21 days (broad mechanism requires longer observation windows)
- Clinical-grade neuroprotective agent; less mechanistically specific than single-target peptides but useful for multi-system depression models